Trial Profile
Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2017
Price :
$35
*
At a glance
- Drugs Plasminogen activators (Primary) ; Ranibizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 31 Mar 2015 New trial record